Search company, investor...
Outlook Therapeutics company logo

Outlook Therapeutics



Total Raised


About Outlook Therapeutics

Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, or mAb, for various ophthalmic indications.

Headquarters Location

7 Clarke Drive

Cranbury, New Jersey, 08512,

United States


Missing: Outlook Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Outlook Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Outlook Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Outlook Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Outlook Therapeutics Patents

Outlook Therapeutics has filed 6 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Disorders of choroid and retina
  • Experimental cancer drugs
patents chart

Application Date

Grant Date


Related Topics




Immune system, Monoclonal antibodies, Immunology, Proteins, Antibodies


Application Date


Grant Date



Related Topics

Immune system, Monoclonal antibodies, Immunology, Proteins, Antibodies



Latest Outlook Therapeutics News

Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank

Mar 13, 2023

Iselin, New Jersey, UNITED STATES ISELIN, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank (“SVB”). Outlook Therapeutics does not hold any deposits or investments at SVB. About Outlook Therapeutics, Inc. Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29, 2023. The submission is supported by Outlook Therapeutics’ wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. As part of the Company’s multi-year commercial planning process, and in anticipation of potential FDA approval in August 2023, Outlook Therapeutics and AmerisourceBergen have entered into a strategic commercialization agreement to expand the Company’s reach for connecting to retina specialists and their patients. AmerisourceBergen will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services in the United States. For more information, please visit . CONTACTS:

Outlook Therapeutics Frequently Asked Questions (FAQ)

  • Where is Outlook Therapeutics's headquarters?

    Outlook Therapeutics's headquarters is located at 7 Clarke Drive, Cranbury.

  • What is Outlook Therapeutics's latest funding round?

    Outlook Therapeutics's latest funding round is PIPE.

  • How much did Outlook Therapeutics raise?

    Outlook Therapeutics raised a total of $51.85M.

  • Who are the investors of Outlook Therapeutics?

    Investors of Outlook Therapeutics include BioLexis, Sabby Capital, Cormorant Asset Management, Proximare, OSSB Pharma Fund and 7 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.